{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:30:28Z","timestamp":1775068228896,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Denosumab is known to cause abnormalities in calcium homeostasis. Most of such cases have been described in patients with underlying chronic kidney disease or severe vitamin D deficiency. Previous bariatric surgery could also contribute to hypocalcemia and deterioration in bone health.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We present a case of a 61-year-old Malay female with worsening bilateral limb weakness, paresthesia, and severe carpopedal spasm a week after receiving subcutaneous denosumab for osteoporosis. She had a history of gastric bypass surgery 20\u00a0years ago. Post gastric bypass surgery, she was advised and initiated on lifelong calcium, vitamin D, and iron supplementations that she unfortunately stopped taking 5\u00a0years after surgery. Her last serum blood tests, prior to initiation on denosumab, were conducted in a different center, and she was told that she had a low calcium level; hence, she was advised to restart her vitamin and mineral supplements. Laboratory workup revealed severe hypocalcemia (adjusted serum calcium of 1.33\u00a0mmol\/L) and mild hypophosphatemia (0.65\u00a0mmol\/L), with normal magnesium and renal function. Electrocardiogram showed a prolonged QTc interval. She required four bolus courses of intravenous calcium gluconate, and three courses of continuous infusions due to retractable severe hypocalcemia (total of 29 vials of 10\u00a0mL of 10% calcium gluconate intravenously). In view of her low vitamin D level of 33\u00a0nmol\/L, she was initiated on a loading dose of cholecalciferol of 50,000\u00a0IU per week for 8\u00a0weeks. However, despite a loading dose of cholecalciferol, multiple bolus courses, and infusions of calcium gluconate, her serum calcium hovered around only 1.8\u00a0mmol\/L. After 8\u00a0days of continuous intravenous infusions of calcium gluconate, high doses of calcitriol 1.5\u00a0\u03bcg twice daily, and 1\u00a0g calcium carbonate three times daily, her serum calcium stabilized at approximately 2.0\u00a0mmol\/L. She remained on these high doses for over 2\u00a0months, before they were gradually titrated down to ensure sustainability of a safe calcium level.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This case report highlights the importance of screening for risk factors for iatrogenic hypocalcemia and ensuring normal levels before initiating denosumab. The patient history of bariatric surgery could have worsened the hypocalcemia, resulting in a more severe presentation and protracted response to oral calcium and vitamin D supplementation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-03764-w","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T01:02:51Z","timestamp":1677718971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Denosumab-induced hypocalcemia post bariatric surgery\u2014a severe and protracted course: a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"Mohd Hazriq","family":"Awang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4508-1436","authenticated-orcid":false,"given":"Sharifah Faradila Wan Muhamad","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimi Fadilah","family":"Mohamad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohana Abdul","family":"Ghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"issue":"4","key":"3764_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00198-019-05261-7","volume":"31","author":"G Tsvetov","year":"2020","unstructured":"Tsvetov G, Amitai O, Shochat T, Shimon I, Akirov A, Diker-Cohen T. Denosumab-induced hypocalcaemia in patients with osteoporosis: can you know who will get low? Osteoporos Int. 2020;31(4):655\u201365.","journal-title":"Osteoporos Int."},{"issue":"8","key":"3764_CR2","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00198-018-4533-6","volume":"29","author":"C Thongprayoon","year":"2018","unstructured":"Thongprayoon C, Acharya P, Acharya C, Chenbhanich J, Bathini T, Boonpheng B, Sharma K, Wijarnpreecha K, Ungprasert P, Gonzalez Suarez ML, Cheungpasitporn W. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. Osteoporos Int. 2018;29(8):1737\u201345.","journal-title":"Osteoporos Int."},{"key":"3764_CR3","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","volume":"51","author":"JJ Body","year":"2015","unstructured":"Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Dami\u00e3o R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer. 2015;51:1812\u201321.","journal-title":"Eur J Cancer."},{"issue":"11","key":"3764_CR4","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1007\/s11695-017-2705-7","volume":"27","author":"M Shah","year":"2017","unstructured":"Shah M, Sharma A, Wermers RA, Kennel KA, Kellogg TA, Mundi MS. Hypocalcaemia after bariatric surgery: prevalence and associated risk factors. Obes Surg. 2017;27(11):2905\u201311.","journal-title":"Obes Surg."},{"key":"3764_CR5","unstructured":"Amgen Inc. Prolia [package insert]. 2015;1\u201331.\nhttps:\/\/www.ema.europa.eu\/en\/documents\/product-information\/prolia-epar-product-information_en.pdf."},{"key":"3764_CR6","unstructured":"Amgen Inc. Xgeva [package insert]. 2014;1\u201320. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xgeva-epar-product-information_en.pdf."},{"issue":"2","key":"3764_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1359\/jbmr.081112","volume":"24","author":"PJ Kostenuik","year":"2009","unstructured":"Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL. J Bone Miner Res. 2009;24(2):182\u201395.","journal-title":"J Bone Miner Res."},{"key":"3764_CR8","volume":"2014","author":"M Muqeet Adnan","year":"2014","unstructured":"Muqeet Adnan M, Bhutta U, Iqbal T, Abdul Mujeeb S, Haragsim L, Amer S. Severe hypocalcaemia due to denosumab in metastatic prostate cancer. Case Rep Nephrol. 2014;2014: 565393.","journal-title":"Case Rep Nephrol"},{"issue":"7","key":"3764_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwi\u0144ski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513\u201323.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"28","key":"3764_CR10","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","volume":"25","author":"A Lipton","year":"2007","unstructured":"Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007;25(28):4431\u20137.","journal-title":"J Clin Oncol."},{"issue":"1 Suppl","key":"3764_CR11","first-page":"S51","volume":"189","author":"K Fizazi","year":"2013","unstructured":"Fizazi K, Bosserman L, Gao G, Skacel T, Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol. 2013;189(1 Suppl):S51\u20137.","journal-title":"J Urol."},{"issue":"1","key":"3764_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4158\/EP.12.1.48","volume":"12","author":"NM Maalouf","year":"2006","unstructured":"Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract. 2006;12(1):48\u201353.","journal-title":"Endocr Pract."},{"issue":"5","key":"3764_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4103\/1319-3767.164183","volume":"21","author":"AA Jammah","year":"2015","unstructured":"Jammah AA. Endocrine and metabolic complications after bariatric surgery. Saudi J Gastroenterol. 2015;21(5):269\u201377.","journal-title":"Saudi J Gastroenterol."},{"issue":"11","key":"3764_CR14","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1007\/s11695-017-2705-7","volume":"27","author":"M Shah","year":"2017","unstructured":"Shah M, Sharma A, Wermers RA, Kennel KA, Kellogg TA, Mundi MS. Hypocalcemia after bariatric surgery: prevalence and associated risk factors. Obes Surg. 2017;27(11):2905\u201311.","journal-title":"Obes Surg."},{"issue":"12","key":"3764_CR15","first-page":"1346","volume":"25","author":"JI Mechanick","year":"2019","unstructured":"Mechanick JI, Apovian C, Brethauer S, Garvey WT, Joffe AM, Kim J, Kushner RF, Lindquist R, Pessah-Pollack R, Seger J, Urman RD, Adams S, Cleek JB, Correa R, Figaro MK, Flanders K, Grams J, Hurley DL, Kothari S, Seger MV, Still CD. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures\u20142019 update: cosponsored by American Association of Clinical Endocrinologists\/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists\u2014executive summary. Endocr Pract. 2019;25(12):1346\u201359.","journal-title":"Endocr Pract."}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03764-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-03764-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03764-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T01:03:32Z","timestamp":1677719012000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-03764-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3764"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-03764-w","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]},"assertion":[{"value":"21 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our institution does not require ethical approval for reporting individual cases or case series.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the\nEditor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}